MedTrace Logo

Retrospective Evaluation of Combination Treatment With the Ulthera System

NCT02444169 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2017-11-24

No results posted yet for this study

Summary

A retrospective study to evaluate the Ulthera® System for its potential interaction with toxins and fillers. Up to 500 subjects will be enrolled.

Conditions

  • Skin Laxity

Interventions

DEVICE

Ultherapy

Focused ultrasound energy delivered below the surface of the skin.

DRUG

Incobotulinumtoxin A

An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.

DEVICE

Radiesse

An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).

DEVICE

Belotero Balance

An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).

Sponsors & Collaborators

  • Ulthera, Inc

    lead INDUSTRY

Principal Investigators

  • Liss Misell, PhD · Ulthera, Inc

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02444169 on ClinicalTrials.gov